Nephros

Nephros Stock-Based Compensation

The Stock-Based Compensation (SBC) of Nephros (NEPH) as of Nov 1, 2026 is 296,000.00 USD. In the previous year, Stock-Based Compensation (SBC) was 153,000.00 USD — a change of 93.46% (higher).

Stock-Based Compensation

296,000.00USD

YoY

93.46%

Last updated:

Stock-Based Compensation (SBC) of Nephros is 2025 296,000.00 USD. Stock-Based Compensation (SBC) of Nephros was 2024 153,000.00 USD. It decreases by 93.46% higher compared to the previous year.

The Nephros Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2018
985,000.00 USD
Jan 1, 2019
1.33 M USD
Jan 1, 2020
779,000.00 USD
Jan 1, 2021
1.26 M USD
Jan 1, 2022
982,000.00 USD
Jan 1, 2023
1.05 M USD
Jan 1, 2024
153,000.00 USD
Jan 1, 2025
296,000.00 USD
The Nephros Stock-Based Compensation history
YEARStock-Based CompensationYoY
296,000.00USD+93.46%
153,000.00USD-85.46%
1.05 MUSD+7.13%
982,000.00USD-22.00%
1.26 MUSD+61.62%
779,000.00USD-41.52%
1.33 MUSD+35.23%
985,000.00USD+27.59%
772,000.00USD+29.31%
597,000.00USD+22.09%
489,000.00USD+13.99%
429,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nephros Stock analysis

What does Nephros do? Nephros, Inc. generates revenue through its Water Filtration and Renal Products segments. The Water Filtration segment sells high-performance water purification filters for hospitals, healthcare facilities, dialysis centers, commercial facilities, military, and outdoor recreation markets. The Renal Products segment offers a second-generation hemodiafiltration system for end-stage renal disease patients. Products include ultrafiltration systems used in medical and commercial applications, with subsidiaries Biocon 1, LLC, Aether Water Systems, LLC, and Specialty Renal Products, Inc. supporting sales and development. The company's water filtration products are sold to hospitals, dialysis centers, and commercial facilities, while the hemodiafiltration system targets healthcare providers treating ESRD patients. Subsidiaries handle specialized development and distribution, ensuring market coverage across medical and commercial sectors. Revenue streams are derived from both segments, with products serving healthcare infrastructure and renal treatment needs. Nephros, Inc. focuses on medical device solutions for renal disease and water purification, leveraging its subsidiaries to expand market reach. The Water Filtration segment serves healthcare and commercial clients, while the Renal Products segment addresses ESRD treatment through advanced hemodiafiltration technology, creating a diversified revenue model. Nephros is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nephros stock

Stock-Based Compensation (SBC) of Nephros is 296,000.00 USD in 2025.

Stock-Based Compensation (SBC) of Nephros changed from 153,000.00 USD to 296,000.00 USD, representing a 93.46% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Nephros since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Nephros historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Nephros

All Key Metrics — Nephros